We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Explore
Metastatic Breast Cancer
Center of Excellence
Interested in receiving weekly updates about the Metastatic Breast Cancer Center of Excellence?
You can find your saved items on your dashboard, in the "saved" tab.
You've recommended your first item
Your recommendations help us improve our content suggestions for you and other PracticeUpdate members.
You've subscribed to your first topic alert
What does that mean?
Each day, we'll check to see if new items have been published to the topics you're subscribed to, and we'll send you one email with all of the new items from that day.
We'll keep all topic alert notifications available on your dashboard for 30 days, to make sure you don't miss anything.
Lastly, whenever you have unread items in the topics you've subscribed to, the "Alerts" icon will light up in the main menu. Just click on the bell to see your five most-recent, unread notifications.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
No comments yet, be the first to start the discussion!
luis betancourt
Aug 19, 2021
Treatment with TE+Ciclins Inhibitors before SBRT ?
nagib khoury
Sep 05, 2021
ET + ABEMA ; better outcomes in liver metastasis and endocrine resistance vs other cdk4-6 inhibitors
Lee Schwartzberg
Sep 09, 2021
Conversion to HER2- is not too common but not rare. I have seen heterogenity in different metastatic lesions which means you may need to continue to biopsy new areas of disease. I don't typically treat 2 liver lesions with SBRT but toxicity is low and is reasonable if small lesions. I would continue OFS and switch to Fulvestrant and a CDK 4/6 inhibitor now. May get prolonged disease control. If recurs, definitely biopsy for standard biomarkers and NGS.
Comment deleted by User.
Comment deleted by Moderator.
Comment deleted by Moderator.
Apr 20, 2024
Pending Moderator approval.
Are you sure you want to delete this comment? This can't be undone.
luis betancourt
Aug 19, 2021
nagib khoury
Sep 05, 2021
Lee Schwartzberg
Sep 09, 2021
Apr 20, 2024
Pending Moderator approval.